Lyon, France, January 3, 2022 – 7:00 p.m. CET – MaaT Pharma (EURONEXT: “MAAT”), a French biotechnology company in advanced clinical stages, pioneer in the development of drugs in the restoration of the intestinal microbiota to improve the survival of patients with cancers, announces today that Hervé Affagard, CEO and co-founder, will present the company at the next HC Wainwright BioConnect virtual conference scheduled for January 10 to 13, 2022.
The presentation will be available on demand via the dedicated HC Wainwright conference website starting Monday, January 10, 2022 at 7:00 a.m. EST / 1:00 p.m. CET.
A replay of the presentation will also be available in the investor area of the company’s website (www.maatpharma.com) from Friday January 14, 2022 and for 90 days.